Onco Wiki / Maladie

Carcinome à cellules basales (CBC)

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDDIS-BCC
TypeMaladie
Alias
BCCCarcinome à cellules basalescancer de la peau des cellules basalesbasaliomeulcère de rongeursБазально-клітинна карцинома (БКК)
Étatreviewed 2026-05-04 | pending_clinical_signoff
MaladiesAucune déclaration
SourcesSRC-NCCN-MELANOMA-2025 SRC-NCCN-SKIN-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_o_3_morphology8090/3
icd_o_3_topography["C44"]
icd_10C44
who_classificationWHO Classification of Skin Tumours 5th ed (2023): Basal cell carcinoma

Capacités

Notes

The vast majority of BCCs are cured with surgery or radiation. Hedgehog inhibitors (vismodegib, sonidegib) are approved only for locally advanced unresectable or metastatic BCC — a small fraction of all BCCs. Gorlin syndrome (PTCH1 germline) warrants genetic counseling and lifelong surveillance. SMO inhibitors cause significant side effects (muscle cramps, alopecia, dysgeusia, weight loss) limiting long-term use. Cemiplimab (anti-PD-1) is FDA-approved for locally advanced/metastatic BCC after HHI failure.

Utilisé par

Pertinence thérapeutique

Algorithmes

Indication

Questionnaires

Signal d’alerte